Soluble E-selectin and P-Selectin Serum Levels in Patients with Psoriasis Compared to Healthy Controls

Introduction: Psoriasis is an inflammatory skin disease in which abnormal individual immune reactivity plays an important role. Eselectin and P-selectin are adhesion molecules expressed on vascular endothelial cells in several inflammatory skin diseases, including psoriasis. The aim of the present study was to describe selected immunological changes, concerning adhesion molecules status (sEselectin, sP-selectin), in psoriasis and also their correlation with disease activity. Method: Serum levels of soluble E-selectin and soluble P-selectin were measured by enzyme-linked immunosorbent assay in 58 patients with psoriasis and 24 healthy control subjects. The relationships between these adhesion molecules and the Psoriasis Areaand Severity Index score were investigated. Result: There was a significant correlation between the serum soluble E-selectin levels and Psoriasis Area and Severity Index score. Conclusion: Soluble E-selectin serum levels correlate with the extent of psoriatic lesions and could be used as marker of the disease activity in psoriatic patients but this finding needs further modification. (Iran J Dermatol 2010;13: 9-11)

[1]  R. Tamagawa‐Mineoka,et al.  Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. , 2010, Journal of the American Academy of Dermatology.

[2]  A. Noël,et al.  Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis. , 2010, Journal of dermatological science.

[3]  A. Gottlieb,et al.  A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. , 2007, Journal of the American Academy of Dermatology.

[4]  A. Langewouters,et al.  Etanercept and efalizumab treatment for high‐need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice , 2007, The Journal of dermatological treatment.

[5]  P. Spuls,et al.  Initial experience with routine administration of etanercept in psoriasis , 2006, The British journal of dermatology.

[6]  J. Barker,et al.  Infliximab for severe, treatment‐resistant psoriasis: a prospective, open‐label study , 2006, The British journal of dermatology.

[7]  Jan Kremláček,et al.  Selected immunological changes in patients with Goeckerman's therapy TNF-alpha, sE-selectin, sP-selectin, sICAM-1 and IL-8. , 2006, Physiological research.

[8]  Wing Hung Wong,et al.  Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. , 2003, Physiological genomics.

[9]  C. Griffiths,et al.  Anti‐E‐selectin is ineffective in the treatment of psoriasis: a randomized trial , 2002, The British journal of dermatology.

[10]  P. Mease,et al.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial , 2000, The Lancet.

[11]  J. Szepietowski,et al.  Soluble E‐selectin serum levels correlate with disease activity in psoriatic patients , 1999, Clinical and experimental dermatology.

[12]  M. Kawashima,et al.  An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasis , 1998, Archives of Dermatological Research.

[13]  A. Kapp,et al.  Soluble E‐selectin in sera of patients with atopic dermatitis and psoriasis—correlation with disease activity , 1996, The British journal of dermatology.

[14]  Franco Ameglio,et al.  Soluble E-selectin and soluble tumour necrosis factor receptor (60 kD) serum levels in patients with psoriasis. , 1995, Dermatology.